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Abstract (150 words) 
 
The congenital myopathies are a genetically heterogeneous and diverse group of 
early-onset, non-dystrophic neuromuscular disorders. Whilst the originally reported 
“classical” entities within this group - Central Core Disease (CCD), Multi-minicore 
Disease (MmD), Nemaline Myopathy (NM) and Centronuclear Myopathy (CNM) – 
were defined by the predominant finding on muscle biopsy, “novel” forms with 
multiple, subtle and unusual histopathological features have been described more 
recently, reflective of an expanding phenotypical spectrum. The main disease 
mechanisms concern excitation-contraction coupling, intracellular calcium 
homeostasis and thin/thick filament interactions.  
Management to date has been mainly supportive. Therapeutic strategies currently at 
various stages of exploration include genetic interventions aimed at direct correction 
of the underlying genetic defect, enzyme replacement therapy and pharmacological 
approaches, either specifically targeting the principal effect of the underlying gene 
mutation, or addressing its downstream consequences more generally. Clinical trial 
development is accelerating but will require more robust natural history data and 
tailored outcome measures.     
 
 
 
 
 
 
 
Introduction 
 
The congenital myopathies (CMs) are a group of genetically heterogeneous, non-
dystrophic conditions with distinct histopathological and highly variable clinical 
features (for review,1). Although onset is typically from birth or early infancy, an 
extremely wide spectrum of severity has been recognized, ranging from profoundly 
severe presentations within the fetal akinesia spectrum to milder forms with onset in 
adolescence or even in adulthood. Whilst most of the CMs are rare, as a group they 
are not uncommon and associated with a substantial individual and societal disease 
burden.  
Reflective of the complex disease associations often involving cardiac, respiratory 
and orthopaedic manifestations, management has been mainly based on a 
multidisciplinary approach involving various medical specialties and allied health 
professionals 2. Whilst such an approach has been highly effective in improving life 
expectancy and quality of life, there is currently no cure. However, in line with other 
neuromuscular disorders, therapy development aimed at correcting or ameliorating 
the underlying genetic defects is accelerating rapidly, and approaching the clinical 
trial stage.  Speed of therapy development in the CMs is influenced by clinical 
urgency, but also the complexity, structure and function of the defective proteins, 
often affecting their suitability for different therapeutic strategies (for review, 3). 
Corresponding to challenges in other early-onset conditions, clinical trial 
development is hampered by the rarity and clinical heterogeneity of individual 
disorders, and the resulting lack of robust natural history data and feasible outcome 
measures.  
The following review will give an overview of the major CMs, their main clinico-
pathological features and the most relevant underlying defects, with an emphasis on 
their suitability for therapeutic modification. Key management principles will be briefly 
outlined and the most relevant therapeutic strategies summarized. Challenges of 
clinical trial design and areas for future research will be highlighted. 
 
The congenital myopathies  
 
The previously well-established concept of the congenital myopathies is currently in 
flux, with important implications for diagnosis, management but also therapy 
development (for review 1): Originally described in the 1950s and 1960s, the major 
disorders within this group – Central Core Disease (CCD), Multi-minicore Disease 
(MmD), Nemaline Myopathy (NM) and Centronuclear Myopathy (NM) – were 
classified based on the predominant histopathological feature on muscle biopsy and 
initially considered distinct and mutually exclusive entities. However, mainly 
prompted by the massively accelerated gene discovery over the last decade, this 
concept has been challenged, and more fluid boundaries, both between “specific” 
CMs but also between the CMs and other neuromuscular disorders, have been 
recognized: With mutations in more than 30 genes identified to date, it has become 
evident that different mutations in the same gene (for example, the gene encoding 
the skeletal muscle ryanodine receptor, RYR1) may give rise to a wide range of 
different, histopathologically defined entities, whereas mutations in different genes 
(for example, those implicated in NM) may give rise to the same CM. Whilst the CMs 
at the point of their original description were considered “pure” histopathological 
entities, it has now also become apparent that those with multiple histopathological 
features in the same muscle biopsy – cores, nemaline rods and central nuclei – are 
at least as, if not more common. Moreover, recent studies based on unbiased next 
generation approaches suggest a hitherto unexpected overlap with other 
neuromuscular conditions, in particular those due to mutations in sodium and 
calcium channel genes associated with periodic paralysis and/or myotonia. Taken 
together, these observations suggest that whilst the “classical” entities may be 
relatively rare, the CMs in a wider sense may be much more common than 
previously estimated.   
The rapid genetic resolution and the changing concepts concerning the CMs are of 
immediate relevance for management and therapy development: For example, as 
certain complications such as an associated cardiomyopathy are more dependent on 
the genetic background than on the histopathological diagnosis, identification of the 
specific gene defect will inform an appropriate management plan and anticipatory 
health surveillance more reliably than the specific muscle biopsy features. Disease 
mechanisms may vary considerably, not only between different genes but also for 
different mutations in the same gene, a notion that must be taken into account with 
regards to the development of therapeutic strategies. Moreover, considering that 
mutations in the same gene may give rise to distinct CMs, gene-focussed therapy 
approaches may be of potential benefit for more than one entity. Finally, the recently 
observed overlap with certain forms of myotonia and periodic paralysis suggests that 
already well-established treatments for these conditions may also be effective in the 
CMs, and that, vice versa, novel CM treatments may be of benefit in other 
neuromuscular disorders.  
   
  
The “classical” congenital myopathies 
 
Central Core Disease (CCD) and Multi-minicore Disease (MmD), often summarily 
referred to as the “core myopathies”  4, are the most common CMs 5. The principal 
histological abnormality, focal reduction of oxidative stain (“cores”), is the same in 
CCD and MmD, but there are important differences both with regards to the number 
of cores on transverse sections and there longitudinal extent. CCD, one of the first 
CMs to be genetically resolved in the early 1990s 6, has been mainly attributed to 
dominant mutations in the skeletal muscle ryanodine receptor (RYR1) gene. MmD, 
on the other hand, is due to recessive mutations in RYR1 7, SEPN1 encoding 
selenoprotein N 8 and, less frequently, MYH7 encoding beta myosin heavy chain 7  9 
and TTN encoding titin 10. Depending on genetic background and mode of 
inheritance, different clinical manifestations have to be anticipated in the 
management of these conditions: Whilst generally a relatively mild condition without 
significant bulbar, cardiac or respiratory involvement, congenital dislocation of the 
hips, scoliosis and tendon Achilles contractures are frequently seen in dominantly 
inherited CCD (for review, 4). SEPN1-related MmD 8, on the other hand, is 
characterized by a rapidly progressive scoliosis and severe respiratory impairment, 
often necessitating spinal fusion and non-invasive ventilation by early adolescence.  
A primary cardiomyopathy has only been observed in MmD related to recessive 
mutations in TTN and MYH7 9,10. Extraocular muscle involvement is mainly a feature 
in RYR1-related MmD.  Muscle MRI may help to differentiate genetically distinct core 
myopathies 11.    
Centronuclear myopathy (CNM) (for review, 12) is characterized by the abundance 
of internalized and centralized nuclei on muscle biopsy, with variable additional 
histopathological features depending on the genetic subgroup. With X-linked 
myotubular myopathy (XLMTM) due to X-linked recessive mutations in myotubularin 
13, the CNMs include one of the most severe CMs, with marked hypotonia and bulbar 
involvement, profound respiratory impairment often necessitating supportive 
ventilation and associated with high mortality. Other relatively common CNM-related 
genetic backgrounds - autosomal-dominant mutations in DNM2 encoding dynamin 2 14 
and BIN1 encoding amphiphysin 2 15, and autosomal-recessive mutations in RYR1 16, 
BIN1 17 and TTN 18 – usually give rise to milder presentations but may mimic the 
XLMTM phenotype in exceptional cases. TTN-related CNM is the only major form that 
may feature a primary cardiomyopathy, but unlike all other major subgroups does not 
have any extraocular muscle involvement. The DNM2-related form may show some 
overlap with an allelic form of CMT, as well as other non-muscular manifestations that 
may also occur in longterm survivors with XLMTM 19.      
Nemaline myopathy (NM), characterized by thread-like structures (“nemaline rods”) 
on muscle biopsy that appear dark with the Gomoeri trichrome stain (for review, 20 
(Dubowitz, Sewry et al. 2013)), is the most genetically diverse CM and has been 
associated with mutations in more than 10 genes. The most common form is due to 
recessive mutations in NEB encoding nebulin 21, and characterized by onset in infancy 
with hypotonia and often pronounced feeding difficulties, with distal lower limb 
involvement, scoliosis and respiratory involvement developing in childhood or 
adolescence 22.  (De novo) dominant mutations in ACTA1 23, encoding skeletal 
muscle alpha actin and the second most common cause, give rise to severe 
neonatal presentations comparable to XLMTM, but milder presentations with later 
onset have also been reported.  Other genetic backgrounds – including dominant 
and recessive mutations in the alpha-tropomyosin (TPM3) 24, the beta-tropomyosin 
(TPM2) 25 and the KBTBD13 26 genes, as well as recessive mutations in slow 
troponin T (TNNT1) 27, cofilin-2 (CFL2) 28, and myopalladin (MYPN) 29 are less 
frequent, often limited to few families or distinct ethnic backgrounds. Recent next 
generation studies into antenatally lethal neuromuscular disorders suggest NM due 
to recessive mutations in KLHL40 30, KLHL41 31 and LMOD3 32 also as a relatively 
common histopathological association of the fetal akinesia sequence. Progressive 
proximal and neck weakness, gait abnormalities, poor exercise tolerance and a 
peculiar slowness of movements are the hallmark of KBTBD13-gene related NM 26, 
which is quite distinct from other forms.  Many of the NM-associated genes have also 
been implicated in distal arthrogryposis (DA) syndromes (for example, 33), a 
reflection of the distal involvement which is common throughout genetically distinct 
forms of NM. Extraocular muscle involvement is not a typical feature, except for 
some cases within the fetal akinesia spectrum. As in the core myopathies, muscle 
MRI may aid distinction between different genetic forms of NM 34.  
 
“Novel” congenital myopathies 
 
Reflective of the increasingly unbiased approach to the genetic investigation of 
patients with unresolved CMs through large-scale next generation sequencing, an 
expanding number of entities has been described with suggestive clinical but not 
always the histopathological features previously considered to be typical (for review, 
1). Within this group of “novel” congenital myopathies, there is also considerable 
overlap with other neuromuscular disorders, in particular the periodic paralyses, 
myotonias, myofibrillar and myosin storage myopathies.     
Congenital myopathies with non-specific, multiple or rare histopathological 
features: A substantial number of patients have been reported with mutations in 
known CM-associated genes but only non-specific histopathological features rather 
than the previously reported, more distinct structural abnormalities (for review, 1); 
these non-specific features include type 1 predominance or uniformity and congenital 
fibre disproportion (CFTD), i.e. often predominant type 1 fibres that are significantly 
and consistently smaller than type 2 fibres. Some CM-associated genes, for example 
RYR1, DNM2 and TTN, may mimic a congenital muscular dystrophy. Certain genetic 
backgrounds may also give rise to combinations of structural abnormalities – cores, 
rods, central nuclei – rather than the “pure” histopathological presentations as 
summarized above. Some very rare histopathological features, caps and zebra 
bodies, have also been attributed to mutations in NM-associated genes.  
Mutations in CACNA1S, previously associated with dominantly inherited periodic 
paralysis and, less frequently, malignant hyperthermia (MH) 35,36, have recently also 
been implicated in CM phenotypes. CACNA1S-related myopathy 37 exists in both 
recessive and dominant forms, and histopathological and clinical features show 
considerable overlap with (recessive) RYR1-related myopathies. Indeed, the 
recognition of CMs as a manifestation of CACNA1S mutations and of periodic 
paralysis as a manifestation of RYR1 mutations, respectively, indicates a consistent 
phenotypical spectrum of mutations in genes encoding essential components of the 
excitation-contraction coupling (ECC) machinery (see below). STIM1- and ORAI1-
related CMs (for review, 38) are multisystem disorders associated with both dominant 
and recessive inheritance; neuromuscular manifestations comprise tubular aggregate 
myopathy (TAM) but also myopathic manifestations with considerable overlap with the 
“classical” CMs.  Recessively inherited, PYROXD1-related CM 39 features 
histopathological features of increased internalized nuclei and myofibrillar 
disorganization and clinical symptoms of a moderately severe CM.  
Hereditary myosin myopathies (“myosinopathies”) (for review, 40) comprise a wide 
range of neuromuscular phenotypes. Amongst those, both dominantly inherited 
MYH7- and recessively inherited MYH2-related myopathies may feature cores on 
muscle biopsy and mimic MmD. There is also substantial overlap between hereditary 
myosinopathies and the DA spectrum. Two other recently described entities with 
histopathological features resembling core myopathies and clinical features in 
between the CM and the DA spectrum include recessively inherited ECEL1-related 
CM 41,42 and dominantly inherited PIEZO2-related CM 43 (also classified as DA5). 
Extraocular muscle involvement is a feature in the latter as well as in MYH2-related 
myopathies and may cause diagnostic confusion with the recessive RYR1-related 
spectrum. Corresponding to the recent expansion of the CACNA1S-related 
spectrum, early-onset, severe SCN4A-related myopathies 44 typically due to loss-
of-function mutations are another example of the expanding phenotypical spectrum 
associated with a gene previously mainly implicated in relatively mild, dominantly 
gain-of-function inherited forms of periodic paralysis and myotonia.   
 
Congenital myopathies and the malignant hyperthermia (MHS) trait 
 
A number of genes – RYR1, and, less frequently, STAC3 and CACNA1S – that have 
been implicated in the CMs have also been linked with the Malignant Hyperthermia 
Susceptibility (MHS) trait, a profoundly severe, pharmacogenetic reaction to volatile 
anaesthetics and depolarizing muscle relaxants (for review, 45). Whilst the link with 
MHS is well-established for dominant RYR1 mutations associated with exertional 
rhabdomyolysis/myalgia (ERM) and some mutations giving rise to CCD, the 
association is less clear for recessively inherited RYR1-related CMs such as MmD, 
CNM and CFTD. However, there is a subset of (often severe, early-onset) RYR1-
related myopathies due to compound heterozygosity for RYR1 mutations that appear 
to behave as dominants with regards to the MHS trait but as recessive with regards to 
the CM phenotypes 46.  Other RYR1-related myopathies with close links to the MHS 
trait include the King-Denborough syndrome (KDS) 47, a dysmorphic syndrome with 
short stature and scoliosis, and a late-onset axial myopathy 48 in previously healthy or 
even particularly athletic individuals compound heterozygous for MHS mutations.  
Another recently recognized myopathy with marked similarities to RYR1-related KDS 
and a high MH risk is Native American myopathy (NAM), originally described in 
native American Indians, the Lumbee population of North Carolina, and due to 
homozygosity for a founder mutation (p.W284S) in STAC3 49.  
 
Pathogenesis 
 
In contrast to the (congenital) muscular dystrophies, the integrity of the muscle 
membrane is usually preserved in the CMs, reflected in typically normal or only 
moderately elevated CK levels. Common pathogenic mechanisms [for review, 1] 
concern intracellular processes ensuring normal muscle maintenance and function, in 
particular excitation-contraction coupling (ECC), the process thereby an electrical 
neuronal impulse is translated into muscle contraction through controlled calcium 
release from the sarcoplasmic reticulum (SR). During ECC, voltage-induced 
conformational changes of the dihydropyridine (DHPR) receptor localized on the 
transverse tubules indirectly lead to opening of the skeletal muscle ryanodine (RyR1) 
receptor, the principal sarcoplasmic reticulum (SR) calcium release channel, and, 
ultimately, muscle contraction through ordered interactions between thin and thick 
filaments. The process is then terminated through calcium reuptake into the SR by 
specialized ATPases, the SERCAs.  
Defects in the genes encoding the key players of ECC - RYR1 and CACNA1S - are 
amongst the most common causes of the CMs: Dominant RYR1 mutations implicated 
in MHS, ERM and subgroups of CCD have been demonstrated to result in a 
hyperexcitable RyR1 receptor and excessive calcium release, whereas in others 
muscle weakness is attributed to constant calcium loss from the SR (“leaky channel 
hypothesis”) and/or uncoupling of DHPR/RyR1 interactions [for review, 50,51]. Whilst the 
mechanisms underlying the more recently described recessive RYR1-related 
myopathies – MmD, CNM, CFTD – are currently less certain, those appear to involve a 
reduction of the functional RyR1 protein rather than malfunctioning of the individual 
RyR1 receptor. Dominant and recessive mutations in CACNA1S 37, encoding the 
CaV1.1 subunit of the DHPR receptor directly interacting with RyR1 in skeletal muscle 
and recently implicated in congenital myopathy phenotypes, have also been associated 
with disturbances of ECC, in particular decreased voltage-induced calcium release and 
reduction of the functional CaV1.1 protein. Mutations in genes encoding accessory 
proteins such as STAC3 49 probably cause weakness through their detrimental effect 
on the regular positioning and functioning of the ECC machinery 52, whereas mutations 
in STIM1 and ORAI1 (for review, 38) affect two alternative pathways of intracellular 
calcium entry indirectly relevant for ECC, Store-Operated Calcium Entry (SOCE) and 
Excitation Contraction Coupled Calcium Entry (ECCE). In addition to these primary 
defects, secondary abnormalities of ECC and intracellular calcium homeostasis have 
also been reported in association with SEPN1 53,54 and the CNM-associated genes 
DNM2 and BIN1.  
Calcium-induced thin and thick filament interactions, the molecular basis of all muscle 
contraction downstream of SR calcium release, are affected by mutations in the major 
genes – NEB, ACTA1 and the tropomyosins – implicated in NM, through structural 
alterations of thin and thick filaments prohibiting their regular assembly or function, 
and/or altering their calcium sensitivity 55-58. Aggregation of abnormal protein is an 
additional factor in the myosinopathies 40, in particular those due to mutations in MYH7, 
and may play a role in other CMs primarily affecting the thin and thick filaments.  
A number of additional pathomechanisms have been described in recent years, both in 
relation to genes implicated in the “classical” CMs but also the more recently described 
“novel” forms. These pathomechanisms include disturbances of myogenesis 59, 
alterations of redox regulation 39,60,61, and abnormalities of intracellular (membrane) 
trafficking and muscle (protein) quality control processes. Many of the more detailed 
mechanisms of how specific genetic backgrounds cause muscle weakness and 
wasting in the CMs, and the precise pathogenic mechanisms underlying the more 
recently identified gene mutations remain currently unresolved. 
 
Management and therapy 
 
Corresponding to other neuromuscular disorders, supportive management provided by 
a multidisciplinary team remains an essential aspect of the approach to the CMs and 
has substantially improved both quality of life and life expectancy. Whilst therapy 
development concerning the neuromuscular field so far has focused on the more 
common and severe conditions (for example, spinal muscular atrophy and Duchenne 
muscular dystrophy), therapies with the potential to improve or even cure the CMs are 
currently being developed. One of the most severe conditions within the congenital 
myopathy spectrum, X-linked myotubular myopathy (XLMTM) has been a particular 
focus of therapy development, and outcomes of ongoing clinical trials are already 
expected in 2018. Therapies designed for the CMs (for review 3) can be grossly divided 
in i) genetic therapies aimed at directly correcting the underlying genetic defect, ii) 
enzyme replacement therapy and iii) pharmacological therapies, including therapies 
that either very specifically target the principal effect of the underlying gene mutation, or 
address its downstream consequences in a more general way, thus being potentially 
applicable to a wider range of CMs rather than one specific entity only. Whilst some of 
these therapies as outlined below already hold considerable therapeutic promise, 
others are at a more conceptual stage and their eventual clinical applicability is 
currently far from certain.  Considering that any of those is unlikely to fully correct the 
disease phenotype on its own and that the downstream consequences of some genetic 
defects are manifold, it is important to bear in mind that combined therapeutic 
approaches will be more likely required rather than focusing on a single approach 
alone. Lastly, as novel therapies will improve life expectancy in affected individuals, 
long-term manifestations of specific CMs potentially expanding the phenotypical 
spectrum will become more obvious, and are likely to require flexible adaptations of 
therapeutic strategies. 
Supportive management of the CMs is not the major focus of the present paper and 
only the key principles are summarized below; more detailed information is available 
from a comprehensive, recently published excellent review of the topic 2. Considering 
often multiple comorbidities, an effectively co-ordinated multidisciplinary approach 
involving various medical and allied health professionals is essential for the effective 
management of the CMs. Supportive management principles are the same throughout 
different forms, with variable emphasis depending on the phenotypical manifestations 
of specific conditions: Joint contractures and scoliosis should be prevented and 
managed through regular physiotherapy input, appropriate seating and orthotic 
support, particularly in conditions where those features are prominent, such as TTN- 
and SEPN1-related myopathies. With a view to potentially beneficial surgical 
interventions, orthopaedic input should be sought early, ideally at a tertiary 
neuromuscular centre experienced with the management of these conditions, including 
respiratory, cardiac and orthopaedic care.  Dysarthria, feeding difficulties and poor 
weight gain are more common at the most severe end of the spectrum and in NM, and 
will benefit from regular speech language therapy input, dietary supplementation and 
gastrostomy insertion where needed. With the notable exception of dominantly 
inherited CCD, respiratory involvement is common throughout different forms and 
should prompt regular respiratory function monitoring (including sleep studies), as well 
as timely institution of (non-invasive) ventilation and, where beneficial, cough assist 
techniques. In contrast to other neuromuscular conditions, respiratory impairment does 
not evolve in parallel to the limb girdle weakness, and may be profound even in 
ambulant patients, particularly in SEPN1- and NEB-related myopathies.  Although 
cardiac involvement is highly variable, regular cardiac monitoring should be performed 
at baseline in all genetically unresolved CMs, and in genetically resolved conditions 
where cardiomyopathies are a prominent recognized feature, particularly in TTN- and 
MYH7-related forms; in these forms, extension of cardiac assessment to relatives may 
also be warranted.  A specific consideration is the potential association of CMs due to 
mutations in RYR1, and, less frequently, STAC3 and CACNA1S with the MHS trait 
(see above) that must be anticipated for pre-operative planning in these patients.  
Genetic therapies: Many of the genes mutated in the CMs such as TTN, NEB or 
RYR1 are amongst the largest in humans, precluding viral-based gene transfer in most 
of these conditions, considering that AAV gene therapy approaches are unsuitable for 
genes with an mRNA over 4.5kb.  Such an approach, delivery of the relatively smaller 
MTM1 gene utilizing an AAV8 vector, has, however, been successfully demonstrated in 
two animal models of XLMTM, the Mtm1-deficient mouse 62 and the naturally occurring 
Labrador retriever model of X-linked myotubular myopathy 63,64. In both instances, viral-
based gene transfer was well-tolerated, and resulted in improvement of clinico-
pathological features in the murine and improved muscle strength, respiratory function 
and survival in the canine model. Considering that the Labrador retriever model shares 
many similarities with human XLMTM, these findings are encouraging, and 
corresponding experimental trials in children with XLMTM have recently started 
(NCT03199469).    
CM forms due to heterozygous dominant negative or gain-of-function mutations – 
including (de novo) dominant forms of RYR1-, and, less frequently, DNM2-, BIN1- and 
MYH7-related myopathies - may benefit from new gene editing strategies  65 once 
those become clinically available.  Based on the observation that carriers of RYR1 null 
mutations are typically asymptomatic 66,67, selective silencing of the mutant allele may 
also become a feasible therapeutic strategy in dominant RYR1-related myopathies, 
particularly in neonatally severe forms due to de novo dominant mutations.  
In those congenital myopathies where nonsense mutations are involved, restoration of 
the mRNA reading frame either through exon skipping (provided the reading frame is 
not disrupted) or through the suppression of premature stop codons could be 
considered to restore a functional protein. This latter approach has for example been 
applied in patients with Duchenne muscular dystrophy due to dystrophin nonsense 
mutation, utilizing the ability of the pharmacological compound PTC124 (or Ataluren) to 
increase premature stop-codon read-through 68, an ability shared with certain 
pharmacologically related but overall more toxic aminoglycosides. A similar approach 
could in theory also be applied to, for example, TTN and NEB nonsense mutations, 
however, it is currently uncertain if the efficacy of compounds such as Ataluren is high 
enough to restore the amount of functional protein sufficiently to achieve a clinical 
relevant improvement of the conditions due to mutations in these genes. These 
considerations are particularly pertinent for proteins with a very short half- life, in 
contrast to stable proteins with longer half-life (such as dystrophin) that obviously 
provide better targets for such an approach. It is also currently uncertain how (and with 
what consequences) general enhancement of premature stop-codon read-through may 
affect the around 20 genes in the human genome that are constitutively inactivated due 
to loss-of-function mutations 69. The remit of exon skipping in restoring the mRNA 
reading frame in the CMs is hampered by, in contrast to for example Duchenne 
Muscular Dystrophy, the relative rarity of specific genetic entities, the private nature of 
many of the causative mutations, and a relatively more complex structure of some of 
the proteins implicated that may not readily tolerate removal of whole constitutive 
exons. As proof-of-principle, exon skipping has, however, been successfully applied to 
remove a paternally inherited pseudo-exon associated with an unstable RyR1 
transcript from the mRNA of a child with a recessive RYR1-related myopathy, resulting 
in increased functional RyR1 protein expression and improved myotube morphology in 
vitro 67; unfortunately, pseudo-exon-creating mutations are estimated at <2% of all 
RYR1 mutations only and practical applicability of this potentially promising approach 
may thus be limited.    
Down- or upregulation of genes acting in related pathways is a strategy currently 
considered for various forms of CNM and in NM secondary to recessive null 
mutations in ACTA1:  The proteins encoded by 3 of the major genes implicated in 
CNM – MTM1, DNM2 and BIN1 – are intricately linked in the same intracellular 
trafficking pathways (for review, 15,70), as demonstrated by the recent observation 
that DNM2 downregulation ameliorates the XLMTM phenotype in mice 71. Based on 
these observations, clinical trials aiming at DNM2 downregulation in XLMTM and, 
possibly, BIN1-related forms of CNM, are currently at the planning stage. Targeting 
of class II and III PI3 kinases acting upstream of myotubularin is another approach 
that has been demonstrated to improve the murine XLMTM phenotype 72 and may 
become a feasible therapeutic strategy in the future.  Patients with recessive ACTA1 
null mutations are rare and partly compensate the absence of skeletal muscle alpha-
action by spontaneous upregulation of ACTAC encoded cardiac actin 73. Based on 
these observations, cardiac alpha-actin upregulation has been investigated in 2 
mouse models of ACTA1-related NM, the D286G and the H40Y line with, however, 
highly variable results 74; the basis of this variability will have to be explored before 
this may be considered as a therapeutic option in affected humans.  
Enzyme replacement therapy (ERT): MTM1 is the only CM-implicated gene 
encoding a protein with predominantly enzymatic function, myotubularin, and 
XLMTM is thus the only CM currently considered for ERT. Mtm1d4 mice have shown 
improvement of histopathological features and contractile function following 
myotubularin ERT 75, providing the basis for human therapy trials currently in 
preparation.      
Pharmacological therapies for the CMs are currently at highly variable stages of 
development and can be subdivided in those aimed at directly modifying altered 
protein function and those aimed at non-specifically ameliorating the often wide 
range of downstream effects of a specific genetic defect.  Considering that some of 
the genes recently implicated in “novel” CMs have been previously associated with 
other neuromuscular disorders (for example, periodic paralyses and myotonias), it is 
conceivable that drugs already established for the treatment of these disorders may 
be repurposed for the treatment of the corresponding CMs. 
Identification of pharmacological compounds aimed at effective direct modification of 
altered protein function is the ultimate aim of any therapy development but currently 
at the early stages only for the CMs and other early-onset neuromuscular disorders. 
Modification of RyR1 receptor calcium release has probably been most widely 
explored based on the longstanding experience with the RyR1 anatagonist 
Dantrolene in the treatment of acute MH crises, exploiting its ability to inhibit 
caffeine-induced ryanodine binding and to reduce the maximum rate of calcium 
release from the SR 76. Case reports suggest that Dantrolene may also be effective 
in the treatment of RYR1-related CCD 77,78, RYR1-related rhabdomyolysis 79-81 and 
probably also the recently described RYR1-related bleeding disorder 82. Other 
compounds that have attracted considerable interest are JTV519 and S107 (also 
known as Rycals), 1,4-benzothiazepine derivates with the ability to modify RyR 
function through their actions on the calstabins. Calstabins exist in 2 isoforms, 
calstabin 1 (or FK506 binding protein 12, FKBP12) mainly expressed in skeletal, and 
calstabin 2 (FKBP12.6) mainly expressed in cardiac muscle 83.  Calstabins exert 
their RyR stabilizing effect when associated with the RyR receptor through 
increasing its closed probability, and their dissociation from the receptor (for 
example, through metabolic modifications at times of stress) result in an increased 
open probability and a “leaky” channel. Rycals promote increased RyR-calstabin 
interactions both in skeletal muscle and the heart, and may thus be suitable for the 
treatment of RYR1-related myopathies associated with increased calcium release 
resulting in depleted SR stores 84.  Another compound to which a RyR1-stabilizing 
effect has been attributed is AICAR (5-aminoimidazole-4-carboximide 
ribonucleoside), a known activator of the AMP-activated protein kinase (AMPK), an 
energy sensor upstream of the autophagy pathway, and a recognized skeletal 
muscle performance enhancer 85. In the RYR1 Y522S mouse, a murine model of 
RYR1-related MH and ERM, AICAR has been found to directly reduce two important 
contributors to the rhabdomyolysis, RyR1 calcium leak and the production of reactive 
nitrogen and oxidatve species 86,87, and may thus be suitable for corresponding 
human RYR1-related phenotypes with similar pathomechanisms.  Despite early 
promise in pre-clinical animal models or isolated cases, no data are currently 
available from larger clinical studies concerning Dantrolene, the Rycals and AICAR, 
and concerns remain regarding their longterm use and safety profiles in humans. 
Moreover, considering that their main mechanism is stabilization of a “leaky” RyR1 
channel, efficacy of these compounds in RYR1-related myopathies associated with 
reduced rather than enhanced calcium conductance is currently uncertain. A number 
of pharmacological compounds targeting thick and thin filament interactions and thus 
promoting force generation 88,89 could potentially be of interest for the NMs but for 
various reasons have not reached the stage of clinical applicability yet: CK-2017357 
(Cytokinetics Inc.) favours myosin activation and contraction by slowing the rate of 
calcium release from Troponin C 90 but preferentially affects type 2 fibres typically 
markedly reduced or absent in NM. CK-1827452 (or Omecamtiv Mecarbil, 
Cytokinetics Inc.) is another compound enhancing myosin activation in a fibre type-
independent manner but also targets cardiac muscle, raising concerns about 
potential cardiac side-effects 91.    
Amelioration of downstream effects is another approach that,  although unlikely to 
cure specific conditions, may be of benefit for CMs with different genetic 
backgrounds that afffect similar mechanisms or pathways. Common downstream 
effects include muscle atrophy both macroscopically and on the single fibre level, 
increased oxidative stress, defective neuromuscular transmission and abnormal 
protein aggregation. Therapeutic strategies to address these common downstream 
manifestations have been devised with variable success, but if effective may also be 
of benefit in other neuromuscular disorders beyond the CMs.  
Reduction of oxidative stress utilizing the antioxidant N-acetylcysteine (NAC) is a 
therapeutic approach based on the observation of increased oxidative stress 
markers in SEPN1- and RYR1-related myopathies, including MH 54,86,92, and 
improvement of both oxidative stress markers and clinical weakness in a zebrafish 
model of recessive RYR1-related myopathies, the relatively relaxed mutant 92. The 
RyR1 receptor has redox-sensing abilities, mediated through a large number of 
cysteine residues that modulate channel activity 93, and a pharmacological effect of 
antioxidants such as NAC is therefore not unexpected. The first clinical studies with 
NAC in humans with RYR1- and SEPN1-related myopathies are currently underway 
[NCT02362425 and NCT02505087, respectively], with unresolved questions 
concerning potential risks of longterm use, in particular in patients with altered stress 
susceptibility such as G6PD deficiency, and decreased weight gain in animal models 
94.   
Structural and functional neuromuscular junction abnormalities have been observed 
with different genetic backgrounds and enhancement of neuromuscular transmission 
with acetylcholine esterase inhibitors has been utilized with some success in various 
forms of CNM, RYR1-related MmD and KLHL40-related NM 95-98, however, the 
number of cases studied so far is small. Some of the beneficial effects of Salbutamol 
– an established treatment modality in certain congenital myasthenic syndromes – 
observed in patients with RYR1-related myopathies 78,99,100 may also at least be 
partly due to its neuromuscular transmission-enhancing properties, although other 
pharmacological properties – for example an anabolic effect as seen in other beta-
mimetics or enhancement of contractility as seen in cardiac muscle 101 – are also 
likely to contribute.   
Muscle atrophy both on the macroscopic and single fibre level is a common feature 
in many CMs and stimulation of muscle growth pathways is therefore at least in 
principle a feasible approach. One class of drugs that have been considered in this 
context are inhibitors of myostatin, a negative regulator of muscle mass 102 
expressed in adipocytes, skeletal and cardiac muscle that downregulates muscle 
growth pathways mediated by its binding to the activin type IIb (ActRIIB) receptor. 
Novel myostatin and ActRIIB inhibitors have been developed that – in addition to a 
potential role in the CMs – may be of potential use in other myopathic, dystrophic 
and neurological disorders where muscle atrophy is a prominent feature. The recent 
observation of altered microRNA (miRs) and histone deacetylase (HDACs) 
expression (i.e. increase of the class II HDACs 4 and 5) in patients with recessive 
RYR1-related and other CMs 103 suggest involvement of additional pathways 
implicated in muscle growth that may be potentially pharmacologically targeted: 
MiRs are small non-coding RNAS with an indirect role in gene regulation, through 
their variable ability to repress translation and/or enhance RNA degradation, and 
have been implicated in a wide range of disease processes, including neuromuscular 
disorders. HDACs may affect muscle growth in different ways, through their actions 
upstream of the autophagy pathway, involvement in gene transcription and 
sequestration of the muscle specific transcription factor mef2 104.            
Aggregation of misfolded proteins is a mechanism that, in contrast to its role for 
example in the myofibrillar myopathies, has not been extensively considered as a 
therapeutic target in the CMs but plays a recognized role in MYH7- 40 and in a subset 
of TTN-related CMs, and is likely to be implicated in the various forms of NM. 
Prevention of protein aggregates and reduction of proteotoxicity, either through 
primarily preventing their aggregation or secondarily promoting their clearance, is 
thus a feasible strategy in these and, possibly, other forms. The available range of 
chemical chaperones with protein-stabilizing qualities is currently still limited, but the 
recent demonstration that the chemical chaperone 4-phenylbutyrate (4-PBA) 
effectively reduces protein aggregation and restores function in PLEC-related 
epidermolysis bullosa simplex with muscular dystrophy (EBS-MD) in vitro 105 
confirms at least the principal usefulness of such compounds. 4-PBA acts through 
several pathways 106, including autophagy induction mediated by HDAC inhibition, 
and it is currently uncertain if the beneficial effect observed in PLEC-mutated cells is 
due to primary prevention of misfolding, increased (autophagy-mediated) clearance, 
or a combination of both.  Interestingly, a beneficial effect of 4PBA has recently also 
been suggested in a mouse model of a RYR1-related myopathy 107. Although the 
number of chemical chaperones is increasing, problems that still need addressing 
concern difficulties achieving pharmacologically relevant concentrations and a 
relative lack of target specificity.   
Other pharmacological approaches include L-Tyrosine supplementation, so far only 
tried in a small cohort of patients with NM 108 based on promising preliminary results 
in a relevant animal model 109, that resulted in some improved secretion 
management but no other obvious functional benefit.  
 
Challenges of therapy development and clinical trial design 
 
Challenges of therapy development and clinical trial planning are the same in the CMs 
as in other early-onset neuromuscular disorders, and reflect the extreme rarity of most 
of these conditions, their genetic heterogeneity, the paucity of detailed natural history 
information and the lack of validated outcome measures.  
Clinical trial design needs to consider the severity of the condition under study and the 
mechanism(s) of action of the chosen intervention. As most of the CMs follow a 
relatively static course with less severe progressive replacement of muscle by 
connective tissue and fat, maintaining stability is a less suitable endpoint compared to 
more severely progressive neuromuscular conditions such as the muscular 
dystrophies. On the other hand, treatments targeting defective EC coupling, one of the 
most commonly implicated disease mechanisms, could result in a discernable increase 
in muscle strength, an outcome measure that can be accurately measured in older 
individuals and thus provide early proof-of-concept of target engagement as well as a 
first indication of clinical efficacy.  
There are only very few clinical trials currently ongoing in the CMs, illustrating some of 
the principles outlined above. An example of a clinical trial targeting a severely affected 
population is the AAV gene therapy trial in XLMTM: In addition to the obligatory safety 
measures as the main emphasis of this Phase 1 trial, outcome measures informed by 
an ongoing natural history study will include validated functional scales, measures of 
respiratory muscle strength, and other secondary measures of motor function. Survival 
and time off ventilator are ultimate endpoints that will also provide a clinical meaning to 
the outcome of this study. The prototype of a trial for a less severe condition in which 
the primary endpoint is to decrease muscle damage and to improve exercise 
tolerance is the N-acetylcysteine (NAC) trial in older individuals (above the age of 7 
and older) with RYR1-related myopathies. This trial will run for a minimum of 12 
months and will include as outcome measures both serum biomarkers of anti-oxidant 
effect (primary), and the 6-minute walk test as a measurement of improved 
endurance (secondary) at an interval following establishment of a baseline. These 
two different studies illustrate the challenges of identifying the most informative 
outcome measure in a profoundly severe condition where improvement is 
unexpected but may be dramatic, and in a milder condition with less potential for 
rapid improvement and lack of baseline data for the selected outcome measure. The 
need to have robust information concerning baseline and outcome measures will 
become increasingly important in CM-related clinical studies, in particular those 
targeting milder and more stable cohort of patients.  
 
Conclusions and outlook 
 
Therapy development in the CMs is currently still in its infancy but opens the realistic 
perspective of a gradual transition from a palliative to a curative approach to these 
conditions. Whilst some of the therapies being developed very specifically target 
distinct genetic entities, others, in particular those focusing on enhancing ECC or 
thin/thick filament interactions, may be of benefit for a wider range of different CMs, 
or even other neuromuscular disorders. Lack of comprehensive natural history data 
and robust outcome measures are the major bottlenecks for effective clinical trial 
planning. Further refinement of currently available genetic approaches, in particular 
viral-based gene transfer and gene editing techniques, are likely to change the 
therapeutic landscape even further in coming years.  
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Figure and Table legends 
 
Figure 1 
Clinical features of RYR1-related myopathies. a) Male infant with recessive 
RYR1-related CNM mimicking XLMTM; b) boy with dominantly inherited RYR1-
related CCD demonstrating a positive Gowers’sign; c-d) male adolescent with a 
personal and family history of (exertional) rhabdomyolysis due to a dominant MH-
associated RYR1 mutation; and e) adult with late-onset axial myopathy due to a 
heterozygous RYR1 mutation. The extremely wide phenotypical spectrum illustrates 
the difficulties obtaining informative natural history data, identifying coherent cohorts 
and reliable outcome measures as a basis for clinical trials. 
 
Table 1 
Main pathogenic mechanisms implicated in the congenital myopathies. 
Common genes and phenotypes are indicated in bold, genes highlighted in red 
indicate those also implicated in the Malignant Hyperthermia Susceptibility (MHS) 
trait. For each mechanism, only the most relevant genetic backgrounds and the most 
commonly associated phenotypes are indicated (for a more comprehensive review, 
also of rarer backgrounds and phenotypes, see 1). Most protein defects implicated in 
the congenital myopathies exert their pathogenic effects through multiple 
mechanisms. * = secondary ECC defects have been described in MTM1-, DNM2- 
and BIN1-related CNM (due to abnormalities of triadic assembly), and in SEPN1-
related myopathies (due to abnormal redox modification of ryanodine receptors). 
ECC = Excitation-contraction coupling; CCD = Central Core Disease, MmD = Multi-
minicore Disease (MmD), CNM = Centronuclear Myopathy, XLMTM = X-linked 
myotubular myopathy; NM = Nemaline Myopathy, CM = congenital myopathy with 
multiple or non-specific features; TAM = Tubular Aggregate Myopathy; MSM = 
Myosin Storage Myopathy; DA = Distal Arthrogryposis; AD = autosomal-dominant; 
AR = autosomal-recessive  
 
Table 2 
Therapeutic approaches to the congenital myopathies. Amongst the therapeutic 
strategies summarized, enzyme replacement therapy (ERT) and viral-based gene 
transfer in X-linked myotubular myopathy (XLMTM), as well as antioxidant therapy in 
RYR1-and SEPN1-related myopathies have already reached (or are approaching) 
the clinical trial stage. * Salbutamol probably exerts its effects through additional 
mechanisms other than enhancement of neuromuscular transmission (see main 
text).  CCD = Central Core Disease, CNM = Centronuclear Myopathy, NM = 
Nemaline Myopathy; AD = autosomal-dominant 
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